Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.

utDNA-positive rate fell from 85% at baseline to 55% pre-cystectomy. Clearance was associated with longer EFS (HR 0.24, 95% CI 0.09-0.62) and was 12 percentage points higher with durvalumab (39% vs 27%). Pre-cystectomy utDNA-negative status was associated with pCR (72% [55/76] vs 18% [17/96] if utDNA-positive). Estimated 24-month EFS was 90% if dual-negative, 75% if utDNA-positive only, and 55% if dual-positive.

ASCO Genitourinary Cancers Symposium 2026